Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
beta-Thalassemia D017086 5 associated lipids
Carotid Stenosis D016893 15 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Yang Deficiency D016711 3 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Yoshino T et al. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. 2005 Arzneimittelforschung pmid:16080279
Mancini F et al. Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings. 2005 Gynecol. Endocrinol. pmid:16019357
Mancini F et al. Effects of hormone replacement therapy on plasma viscosity and Doppler variations in postmenopausal non-smokers and heavy smokers. 2005 Gynecol. Endocrinol. pmid:16019365
Michibayashi T Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways. 2005 J. Atheroscler. Thromb. pmid:16020916
Svenstrup Poulsen T et al. A critical appraisal of the phenomenon of aspirin resistance. 2005 Cardiology pmid:16020925
Walsh DS et al. Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. 2005 J. Surg. Res. pmid:16045935
Rodrigue ME et al. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. 2005 Can. J. Physiol. Pharmacol. pmid:16049546
Esser R et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. 2005 Br. J. Pharmacol. pmid:15655513
Sullivan JC et al. Sexual dimorphism in renal production of prostanoids in spontaneously hypertensive rats. 2005 Hypertension pmid:15699443
Chan CP et al. Inhibition of cyclooxygenase activity, platelet aggregation and thromboxane B2 production by two environmental toxicants: m- and o-cresol. 2005 Toxicology pmid:15664436
Massicot F et al. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. 2005 Basic Clin. Pharmacol. Toxicol. pmid:15667592
Lee GY et al. Antiplatelet activity of BRX-018, (6aS,cis)-malonic acid 3-acetoxy-6a9-bis-(2-methoxycarbonyl-acetoxy)-6,6a,7,11b-tetrahydro-indeno[2,1-c]chromen-10-yl ester methylester. 2005 Thromb. Res. pmid:15668191
Gama de Abreu M et al. Vaporized perfluorohexane attenuates ventilator-induced lung injury in isolated, perfused rabbit lungs. 2005 Anesthesiology pmid:15731599
Ye T et al. [Insulin resistance and effects of intravenous acute saline load on renal production of prostaglandin I2 and thromboxane A2 in salt-sensitive hypertensive patients]. 2005 Di Yi Jun Yi Da Xue Xue Bao pmid:15684012
Montuschi P et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. 2005 Thorax pmid:16192367
Barbara J et al. Prevention of latex sensitization in guinea pigs by a bacterial and viral filter used in anaesthesia. 2005 Br J Anaesth pmid:15980041
Hsiao G et al. alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation. 2005 J. Agric. Food Chem. pmid:15969494
Munsterhjelm E et al. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. 2005 Acta Anaesthesiol Scand pmid:15954969
Vangroenweghe F et al. Effect of carprofen treatment following experimentally induced Escherichia coli mastitis in primiparous cows. 2005 J. Dairy Sci. pmid:15956299
Wakamoto S et al. Effects of hemoglobin vesicles on resting and agonist-stimulated human platelets in vitro. 2005 Artif Cells Blood Substit Immobil Biotechnol pmid:15960075
Al Kadi H et al. A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight. 2005 Hum. Reprod. pmid:16006463
Beretta C et al. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. 2005 Pharmacol. Res. pmid:15939622
Klein Gunnewiek JM et al. The influence of acetylsalicylic acid intake by healthy volunteers on duplicate PFA-100 measurements. 2005 Blood Coagul. Fibrinolysis pmid:15970717
Jin YR et al. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. 2005 Basic Clin. Pharmacol. Toxicol. pmid:16128910
Francois H et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. 2005 Cell Metab. pmid:16154102
Jermany J et al. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. 2005 J Clin Pharmacol pmid:16172182
Persico N et al. Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. 2005 Ultrasound Obstet Gynecol pmid:16184506
Perini JA et al. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. 2005 Clin. Pharmacol. Ther. pmid:16198655
Davì G et al. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15472127
Maree AO et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. 2005 J. Am. Coll. Cardiol. pmid:16198840
Kataoka M et al. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. 2005 Am. J. Respir. Crit. Care Med. pmid:16192456
Munsterhjelm E et al. Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. 2005 Anesthesiology pmid:16192763
Hsiao G et al. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. 2005 J. Lab. Clin. Med. pmid:16194683
Xiaorong C et al. Effects of medicinal cake-separated moxibustion on plasma 6-keto-PGF1alpha and TXB2 contents in the rabbit of hyperlipemia. 2005 J Tradit Chin Med pmid:16136949
Stichtenoth DO et al. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. 2005 Kidney Int. pmid:16221219
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Trebino CE et al. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. 2005 J. Biol. Chem. pmid:15722356
Kalaitzis C et al. Effects of renal denervation of the contralateral kidney on blood pressure and sodium and eicosanoid excretion in the chronic phase of two-kidney, one-clip renovascular hypertension in rats. 2005 Scand. J. Urol. Nephrol. pmid:15764265
García-Saura MF et al. Effects of chronic quercetin treatment in experimental renovascular hypertension. 2005 Mol. Cell. Biochem. pmid:15792364
Awad AS et al. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. 2005 Am. J. Hypertens. pmid:15831366
De Candia E et al. Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. 2005 Int. J. Cardiol. pmid:15837078
Capone ML et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. 2005 J. Am. Coll. Cardiol. pmid:15837265
Oliveira RL et al. Postmenopausal hormone replacement therapy increases plasmatic thromboxane beta 2. 2005 Int. J. Cardiol. pmid:15771927
Cryer B et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. 2005 Clin Ther pmid:15811481
Watanabe H et al. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. 2005 Circ. J. pmid:15635218
Lappegård KT et al. Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. 2005 Ann. Thorac. Surg. pmid:15734405
Maruyama T et al. Thromboxane-dependent portopulmonary hypertension. 2005 Am. J. Med. pmid:15639216
Falco A et al. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. 2005 Atherosclerosis pmid:16285996
Noguchi M et al. Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites. 2005 Biol. Pharm. Bull. pmid:16272692
Ando K [Synthesis of 2-, 4- and 5-(2-alkylcarbamoyl-1-methylvinyl)-7-alkyloxybenzo[b]furans and their leukotriene B4 receptor antagonistic activity]. 2005 Yakugaku Zasshi pmid:16272807